Treatment of Herpes Zoster

First-Line Treatment

• The American College of Physicians recommends oral valacyclovir 1 gram three times daily for 7 days as the first-line treatment for uncomplicated herpes zoster, initiated within 72 hours of rash onset 1, 2
• Alternative oral antiviral options include acyclovir 800 mg orally five times daily for 7-10 days and famciclovir 500 mg every 8 hours for 7 days 1, 2

Critical Treatment Timing and Duration

• Treatment must be initiated within 72 hours of rash onset for optimal efficacy in reducing acute pain, accelerating lesion healing, and preventing postherpetic neuralgia 1, 2
• Continue treatment until all lesions have completely scabbed, not just for an arbitrary 7-day period—this is the key clinical endpoint 1, 2

Escalation to Intravenous Therapy

• Intravenous acyclovir 5-10 mg/kg every 8 hours is mandatory for disseminated or invasive herpes zoster, severely immunocompromised patients, complicated facial zoster, and patients who cannot tolerate or absorb oral medications 1, 2
• For IV therapy, continue treatment for a minimum of 7-10 days and until clinical resolution is attained, then switch to oral therapy once clinical improvement occurs 1, 2

Special Population Considerations

• All immunocompromised patients with herpes zoster require antiviral treatment regardless of timing beyond the 72-hour window 2
• Consider temporary reduction or discontinuation of immunosuppressive medications in cases of disseminated or invasive disease if clinically feasible 1, 2

Adjunctive Pain Management

• Topical anesthetics provide minimal benefit and are not recommended as primary therapy for acute zoster pain 1

Role of Corticosteroids

• Corticosteroids offer only modest benefits and carry significant risks, and should be avoided in immunocompromised patients due to increased risk of disseminated infection 1

Treatment Failures and Resistance

• If lesions fail to begin resolving within 7-10 days, suspect acyclovir resistance and obtain viral culture with susceptibility testing 1
• For confirmed acyclovir-resistant herpes zoster, foscarnet 40 mg/kg IV every 8 hours is the treatment of choice 1, 2

Prevention Strategies

• The recombinant zoster vaccine (Shingrix) is strongly recommended for all adults aged 50 years and older, regardless of prior herpes zoster episodes, and provides >90% efficacy in preventing future recurrences 1, 2, 3

Infection Control

• Patients should avoid contact with susceptible individuals until all lesions have crusted, as lesions are contagious to those who have not had chickenpox or vaccination 1

Common Pitfalls to Avoid

• Do not use topical antiviral therapy—it is substantially less effective than systemic therapy 1, 2
• Do not discontinue treatment at exactly 7 days if lesions are still forming or have not completely scabbed—treatment duration should be guided by lesion healing, not calendar days 1, 2

Bacterial Superinfection in Fever with Herpes Zoster

Assessment and Management

• In otherwise healthy adults presenting with fever and herpes zoster, clinicians should evaluate for signs of bacterial superinfection (e.g., purulent discharge, expanding erythema, localized warmth) and, when present, add appropriate antibiotic therapy to the antiviral regimen to address the secondary infection 4